Peptide-Based Infection Therapeutics Market By Drug Type (Antimicrobial Peptides, Cationic Peptides, Lipopeptides), By Application (Bacterial Infections, Viral Infections, Fungal Infections), By End-User (Hospitals & Clinics, Infectious Disease Research Centers, Pharmaceutical Companies), By Distribution Channel (Direct Sales, Distributors, Online Retailers), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Peptide-Based Infection Therapeutics Market was valued at USD 2.6 billion in 2024-e and will surpass USD 4.1 billion by 2030; growing at a CAGR of 7.9% during 2025 - 2030.

The peptide-based infection therapeutics market is witnessing significant growth, driven by the increasing prevalence of infectious diseases and the limitations of traditional antimicrobial agents. Peptide-based therapeutics, including antimicrobial peptides, cationic peptides, and lipopeptides, offer promising alternatives to conventional antibiotics, particularly in the face of rising antibiotic resistance. These peptides possess the ability to target and neutralize a wide range of pathogens, including bacteria, viruses, and fungi, making them a versatile and effective treatment option for infections.

As the global burden of infectious diseases continues to rise, the demand for novel therapies is increasing. The ability of peptide-based drugs to target multiple pathogens with lower resistance profiles positions them as a promising solution to address the growing concerns around drug-resistant infections. The market is poised for growth, with ongoing research focusing on improving the efficacy, stability, and delivery of peptide-based infection therapeutics.

Antimicrobial Peptides Segment Dominates the Market Due to Broad-Spectrum Activity

The antimicrobial peptides segment holds the largest share in the peptide-based infection therapeutics market, driven by their broad-spectrum activity against a wide range of pathogens. Antimicrobial peptides are naturally occurring molecules that exhibit potent antimicrobial activity, making them effective against bacterial, viral, and fungal infections. Their ability to target microbial membranes and disrupt pathogen viability gives them a significant advantage over traditional antibiotics.

Antimicrobial peptides are also being extensively researched for their potential in treating multidrug-resistant infections, which are becoming increasingly difficult to manage with conventional antibiotics. Their versatility and effectiveness in combating a wide array of infectious agents have positioned antimicrobial peptides as the cornerstone of peptide-based infection therapeutics, driving their dominance in the market.

Bacterial Infections Application Segment is the Largest and Fastest Growing

The bacterial infections application segment is the largest and fastest-growing segment in the peptide-based infection therapeutics market. Bacterial infections, including those caused by resistant strains such as MRSA (Methicillin-resistant Staphylococcus aureus), are a significant global health concern. The rise of antibiotic-resistant bacteria has created an urgent need for new treatment options.

Peptide-based therapies, particularly antimicrobial and cationic peptides, are gaining traction for their ability to combat bacterial infections by disrupting bacterial cell membranes and inhibiting bacterial growth. The increasing prevalence of bacterial infections, coupled with the growing threat of antibiotic resistance, is driving the demand for peptide-based drugs in the treatment of bacterial infections. This trend is expected to continue as more research demonstrates the potential of peptides in treating difficult-to-treat bacterial infections.

Hospitals & Clinics Segment is the Largest End-User Due to Direct Patient Care

The hospitals and clinics segment is the largest end-user of peptide-based infection therapeutics, owing to their direct role in providing patient care and managing infections. Hospitals and clinics are the primary healthcare settings where patients suffering from bacterial, viral, and fungal infections are diagnosed and treated. The infrastructure available in these settings, along with the expertise of healthcare providers, makes them the primary locations for administering peptide-based therapeutics.

Moreover, hospitals and clinics are central to the management of severe or complicated infections, particularly those caused by multidrug-resistant pathogens. Peptide-based infection therapeutics are increasingly being incorporated into treatment regimens for patients with infections that are difficult to treat with conventional antibiotics, driving the market demand in these healthcare settings.

North America Leads the Market Due to Advanced Healthcare Infrastructure and Research

North America is the leading region in the peptide-based infection therapeutics market, driven by its advanced healthcare infrastructure, high healthcare spending, and a strong research and development ecosystem. The United States, in particular, is home to several leading pharmaceutical companies and research institutions focused on the development of peptide-based infection therapies.

The region's focus on addressing the growing problem of antibiotic resistance has led to significant investments in the research and development of peptide-based drugs. Furthermore, the high incidence of bacterial, viral, and fungal infections in North America, along with the increasing prevalence of multidrug-resistant organisms, is propelling the demand for peptide-based therapeutics. As a result, North America remains the dominant market for peptide-based infection therapeutics.

Competitive Landscape

The peptide-based infection therapeutics market is highly competitive, with several key players engaged in the development and commercialization of peptide-based drugs for treating infectious diseases. Companies are focusing on the discovery and optimization of novel peptides with enhanced antimicrobial activity, stability, and bioavailability. Additionally, advancements in peptide drug delivery systems are helping to improve the therapeutic efficacy of these agents.

Leading pharmaceutical and biotechnology companies are investing heavily in research and development to explore the full potential of peptide-based therapeutics in treating bacterial, viral, and fungal infections. In addition to large companies, smaller biotech firms are also playing a crucial role in developing innovative peptide-based drugs. The competitive landscape is shaped by factors such as regulatory approvals, pricing strategies, and the ability to bring new and effective therapies to market. The growing threat of antibiotic resistance and the demand for alternative treatments are expected to drive ongoing innovation and competition within the peptide-based infection therapeutics market.

List of Leading Companies:

• Novartis
• Pfizer
• Merck & Co.
• Roche
• Johnson & Johnson
• GlaxoSmithKline
• Amgen Inc.
• Bristol-Myers Squibb
• Sanofi
• Eli Lilly and Company
• Abbott Laboratories
• AstraZeneca
• Boehringer Ingelheim
• Gilead Sciences
• Teva Pharmaceutical Industries

Recent Developments:

• In December 2024, Novartis launched a new antimicrobial peptide-based treatment for drug-resistant bacterial infections.
• In November 2024, Pfizer received approval for a peptide-based antifungal drug for severe fungal infections.
• In October 2024, Merck & Co. introduced a new lipopeptide-based therapeutic for viral infections.
• In September 2024, Roche expanded its portfolio of peptide-based infection therapeutics to include a novel treatment for bacterial superbugs.
• In August 2024, Johnson & Johnson entered into a partnership to develop peptide antibiotics targeting multi-drug-resistant infections.

Report Scope: